House bill would require Medicaid providers to give parents FDA medication guide and written consent for psychotropic drugs for minors

House lawmakers heard testimony on HB 732-FN on parental notification for psychotropic medications, a bill that would require providers prescribing those drugs to Medicaid-enrolled minors to review the FDA medication guide with a parent or legal guardian and obtain written consent.

Supporters said the bill aims to increase parental awareness of risks associated with psychotropic medications; state Medicaid officials and other witnesses raised concerns about narrow scope, administrative costs and how consent works when children are in out-of-home placements.

Representative Glenn Cordelli, the bill’s prime sponsor, told the committee the measure is “about parents’ rights and transparency” and said psychotropic drugs are already defined in statute as medicines prescribed to treat conditions that affect “psychological functioning, perception, behavior or mood.” He recommended that providers “review the FDA guideline for that medication with the parent and obtain their written consent knowing the risks and potential side effects of the medication.”

Cordelli used the FDA medication guide for methylphenidate (Ritalin) as an example, saying the guides list warnings and precautions including “abuse, misuse, addiction” and other risks. He told the panel the law would not take effect immediately and would give providers time to prepare.

Representative Lucy Weber, speaking in committee, asked for confirmation of the bill’s mechanics: whether a provider prescribing Ritalin would be required to present the medication guide, go over it and document that the parent had signed. Cordelli replied, “That is correct.”

David Chorney, identified in testimony as the deputy Medicaid director for New Hampshire, told the committee the bill as written would apply only to Medicaid-enrolled children, a group he said is “less than 1 in 4 children in New Hampshire.” Chorney warned that applying a higher consent standard only to Medicaid patients could create provider “abrasion” — different workflows for a subset of a clinician’s panel — and could harm access if clinicians declined to treat Medicaid patients or altered practice patterns.

Chorney also raised implementation questions the bill did not specify: advanced practice registered nurses prescribe psychotropic medicines in some cases, and the bill’s reporting and enforcement steps appear to assume oversight channels that do not cover those prescribers. He noted Medicaid’s retroactive enrollment mechanism, which can make patients Medicaid-eligible up to 90 days before enrollment, and suggested the bill should account for that scenario.

Margaret Clifford, presenting as pharmacy director for New Hampshire Medicaid, told the committee she understood the bill to require only the FDA medication guide page appended to the handout rather than the entire FDA package insert, which she said would narrow the material providers must review with parents.

Multiple committee members pressed Cordelli on how the bill would apply when parents are not involved in a child’s care. Representative Weber and others asked how consent works where children are in out-of-home placements and parental rights are the subject of ongoing litigation. Cordelli said DCYF (the Division for Children, Youth and Families) oversees medication for children in out-of-home placements and that, in practice, a DCYF case manager may handle medication review in those cases, but he acknowledged the committee could add clarifying language to address such circumstances.

Testimony also flagged emergency-care scenarios, where witnesses said obtaining enhanced informed consent at the point of care might not be practicable; Chorney and other witnesses asked the committee to consider exceptions for emergencies.

Supporters provided letters of support, including one from an FDA drug-advisory consumer representative Cordelli said he had attempted to mail to the committee. The public hearing closed with no vote recorded; the committee recessed to other business.

Where things stand: the committee took testimony and closed the public hearing; proponents and Medicaid officials signaled willingness to draft clarifying amendments to address DCYF authority, retroactive enrollment and prescriber scope before any committee vote.